4//SEC Filing
Fenton Mary Kay 4
Accession 0001209191-23-041617
CIK 0001827506other
Filed
Jul 5, 8:00 PM ET
Accepted
Jul 6, 5:20 PM ET
Size
5.2 KB
Accession
0001209191-23-041617
Insider Transaction Report
Form 4
Fenton Mary Kay
Chief Financial Officer
Transactions
- Tax Payment
Common Stock
2023-07-03$3.08/sh−12,946$39,874→ 68,054 total
Footnotes (1)
- [F1]The restricted stock units ("RSUs") were granted to the Reporting Person by the issuer under the Issuer's 2021 Stock Option and Incentive Plan on September 10, 2022. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. This transaction reflects the sufficient shares sold to pay applicable income taxes related to the 50% vesting on July 1, 2023.
Documents
Issuer
Talaris Therapeutics, Inc.
CIK 0001827506
Entity typeother
Related Parties
1- filerCIK 0001378589
Filing Metadata
- Form type
- 4
- Filed
- Jul 5, 8:00 PM ET
- Accepted
- Jul 6, 5:20 PM ET
- Size
- 5.2 KB